Selvita S.A.

Warsaw Stock Exchange SLV.WA

Selvita S.A. Operating Cash Flow for the year ending December 31, 2023: USD 20.03 M

Selvita S.A. Operating Cash Flow is USD 20.03 M for the year ending December 31, 2023, a 16.34% change year over year. Operating cash flow is cash generated from the company’s regular business operations.
  • Selvita S.A. Operating Cash Flow for the year ending December 31, 2022 was USD 17.22 M, a -20.44% change year over year.
  • Selvita S.A. Operating Cash Flow for the year ending December 31, 2021 was USD 21.64 M, a 175.32% change year over year.
  • Selvita S.A. Operating Cash Flow for the year ending December 31, 2020 was USD 7.86 M, a 594.75% change year over year.
  • Selvita S.A. Operating Cash Flow for the year ending December 31, 2019 was USD 1.13 M, a -63.45% change year over year.
Key data
Date Operating Cash Flow Net Cash Used For Investing Activities Net Cash Used Provided By Financing Activities Dividends Paid
Market news
Loading...
SV Wall Street
Warsaw Stock Exchange: SLV.WA

Selvita S.A.

CEO Mr. Boguslaw Stanislaw Sieczkowski M.B.A.
IPO Date Oct. 17, 2019
Location Poland
Headquarters ul. Bobrzynskiego 14
Employees 886
Sector Healthcare
Industries
Description

Selvita S.A. operates as a contract research organization in Poland, rest of Europe, the United States, and internationally. It operates in two segments, Contract Research Organization (CRO) services, and Bioinformatics. The company offers drug discovery services in the areas of assay development and screening, medicinal and synthetic chemistry, computer-aided drug design/ artificial intelligence, structural biology, in vitro/ In Vivo pharmacology, ADME/DMPK and analytical testing. It also provides pharma services in the field of drug testing and bioanalytical analysis, including development and optimization, validation and transfer, stability studies, quality control, and regulatory aspects support services. In addition, the company offers research and development services in the areas of process research, laboratory scale custom synthesis of NCEs, industrial chemistry, and synthesis of isotopically labelled compounds, as well as other services for the agrochemical industry. Further, it provides bio-data science and advanced software services to data-driven life science and healthcare organizations. Selvita S.A. was founded in 2007 and is headquartered in Krakow, Poland.

Similar companies

MBR.WA

Mo-BRUK S.A.

USD 86.63

-3.32%

NEU.WA

NEUCA S.A.

USD 206.65

-0.03%

RVU.WA

Ryvu Therapeutics S.A.

USD 6.53

2.36%

ACP.WA

Asseco Poland S.A.

USD 27.97

-3.68%

KTY.WA

Grupa Kety S.A.

USD 180.40

-3.69%

StockViz Staff

February 6, 2025

Any question? Send us an email